The J.M. Smucker Company (SJM) Faces Investor Scrutiny After Announcing The Second Hostess-Related Impairments In About 3 Months - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 18, 2025) - On June 10, 2025 investors in The J.M. Smucker Company (NYSE: SJM) saw the price of their shares decline over 15% after the company announced disappointing Q4 2025 financial results.This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether SJM may have violated the securities laws concerning the propriety of its statements about the benefits of the Hostess Brands acquisition. The firm urges SJM investors...
2025-07-18 12:30 PM EDT
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 18, 2025) - When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder.Since the May 27 announcement,...
2025-07-18 12:27 PM EDT
Hims & Hers Health, Inc. (HIMS) Alleged "Deceptive" Marketing of Wegovy(R) Triggers Securities Class Actions - HIMS Investors with Losses Encouraged to Contact Hagens Berman
San Francisco, California--(Newsfile Corp. - July 18, 2025) - On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. The cases seeks to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated...
2025-07-18 12:26 PM EDT
CTO Realty Growth, Inc. (CTO) Shares Decline Amid Wolfpack Report - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 16, 2025) - On June 25, 2025 investors in CTO Realty Growth, Inc. (NYSE: CTO) saw the price of their shares significantly decline after Wolfpack Research published CTO: The B. Riley Of REITS, accusing CTO of misleading investors about its dividend sustainability and engaging in dubious financial activities.This report has prompted national shareholders rights firm Hagens Berman to open an investigation into the allegations and whether CTO may have violated the securities laws....
2025-07-16 3:14 PM EDT
BellRing Brands (BRBR) Shares Declined 19% Amid Upcoming Retailer Destocking - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 16, 2025) - On May 6, 2025, investors in BellRing Brands, Inc. (NYSE: BRBR) saw the price of their shares decline about 19% after BellRing announced during its Q2 2025 earnings call that it anticipated Q3 2025 reduction in retailer inventory levels.This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether BellRing Brands may have violated the securities laws concerning the company's sales practices. The firm urges BellRing...
2025-07-16 3:13 PM EDT
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 15, 2025) - A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company's announcement...
2025-07-15 8:30 AM EDT
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy(R)- Hagens Berman
San Francisco, California--(Newsfile Corp. - July 15, 2025) - On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29,...
2025-07-15 8:18 AM EDT
IOVA 3-DAY DEADLINE ALERT: Hagens Berman Reminds Iovance (IOVA) Investors of Pending Securities Class Action, Encourages Investors with Losses to Contact the Firm
San Francisco, California--(Newsfile Corp. - July 11, 2025) - Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the...
2025-07-11 10:16 AM EDT
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy(R)- Hagens Berman
San Francisco, California--(Newsfile Corp. - July 8, 2025) - On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29,...
2025-07-08 7:16 PM EDT
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 8, 2025) - A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company's announcement...
2025-07-08 7:08 PM EDT
IOVA SHAREHOLDER ALERT: Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure- Hagens Berman
San Francisco, California--(Newsfile Corp. - July 7, 2025) - Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the...
2025-07-07 9:16 AM EDT
Compass Diversified (CODI) Situation Worsens, Admits Accounting Irregularities During 2022 - 2024, Expanded Class Period In Amended Securities Class Action Complaint - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 7, 2025) - After hours on June 25, 2025, Connecticut-based private equity firm Compass Diversified (NYSE: CODI) filed a report with the SEC warning investors not to rely on previously issued financial statements for its fiscal years ended- and interim periods within- December 31, 2022 and 2023, citing an expanded scope of previously disclosed accounting irregularities. The firm is navigating a turbulent period marked a precipitous stock decline, burgeoning class-action lawsuits, and recent accounting...
2025-07-07 9:14 AM EDT
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 3, 2025) - A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company's announcement...
2025-07-03 1:21 PM EDT
BellRing Brands (BRBR) Shares Declined 19% Amid Upcoming Retailer Destocking - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 2, 2025) - On May 6, 2025, investors in BellRing Brands, Inc. (NYSE: BRBR) saw the price of their shares decline about 19% after BellRing announced during its Q2 2025 earnings call that it anticipated Q3 2025 reduction in retailer inventory levels.This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether BellRing Brands may have violated the securities laws concerning the company's sales practices. The firm urges BellRing...
2025-07-02 5:39 PM EDT
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy(R) - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 1, 2025) - On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29,...
2025-07-01 5:04 PM EDT
IOVA 13-DAY DEADLINE ALERT: Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 1, 2025) - Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the...
2025-07-01 4:50 PM EDT
Compass Diversified (CODI) Situation Worsens, Admits Accounting Irregularities During 2022 - 2024, Expanded Class Period in Amended Securities Class Action Complaint - Hagens Berman
San Francisco, California--(Newsfile Corp. - June 30, 2025) - After hours on June 25, 2025, Connecticut-based private equity firm Compass Diversified (NYSE: CODI) filed a report with the SEC warning investors not to rely on previously issued financial statements for its fiscal years ended- and interim periods within- December 31, 2022 and 2023, citing an expanded scope of previously disclosed accounting irregularities.The firm is navigating a turbulent period marked a precipitous stock decline, burgeoning class-action lawsuits, and recent accounting malfeasance...
2025-06-30 12:21 PM EDT
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
San Francisco, California--(Newsfile Corp. - June 26, 2025) - A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company's announcement...
2025-06-26 9:21 AM EDT
CODI 2-WEEK DEADLINE ALERT: Compass Diversified (CODI) Grapples with Financial Irregularities, Slashes Dividend Amid Investor Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - June 24, 2025) - Compass Diversified (NYSE: CODI), a Connecticut-based private equity firm, is navigating a turbulent period marked by the recent resignation of a key director, a precipitous stock decline, and a burgeoning class-action lawsuit, all stemming from unearthed accounting irregularities at one of its portfolio companies.Hagens Berman is investigating the claims and urges investors who purchased Compass shares and suffered substantial losses to submit your losses now.Class Period: May 1, 2024 - May...
2025-06-24 1:41 PM EDT
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure - Hagens Berman
San Francisco, California--(Newsfile Corp. - June 24, 2025) - Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the...
2025-06-24 1:36 PM EDT